Coronavirus (COVID-19) Update

This is an incredibly challenging time, but at MannKind, it has also deepened our passion for helping people with diabetes. Please see below for a compilation of all applicable resources.


Virtual Training + Resources

Given the current circumstances, many may be unable or unwilling to visit the offices of healthcare providers during this time. As always, the MannKind Customer Experience Center offers all of its services virtually.

You can schedule a free virtual training to help you get started with Afrezza®.


You can also explore our library of self-guided training videos and resources.


Paying for Afrezza

Whether you’ve lost or changed insurance, are worried about continuing to be able to get your Afrezza®, or are experiencing a unique challenge – the MannKind Customer Experience Center is here for you. MannKind offers several support options which may be available to you, depending on your insurance and circumstance, to help you navigate the current coronavirus situation.

Call or make a free appointment with the MannKind Customer Experience Center to discuss what options may be available to you.

Call toll-free:

(833) 623-4843


Please note: If the MannKind Customer Experience Center is unable to answer at the time of your call, please leave us a voicemail and we will follow up with you within 1 business day. You can also use our online scheduler to make an appointment to get help when it’s convenient for you. We appreciate your understanding while we help all our customers. Please visit https://afrezza.com/faqs to find answers to product-related questions.   


Supply of Afrezza

With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind anticipates a stable supply of Afrezza® that will not be affected by the coronavirus pandemic.

We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza®. MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies.

Afrezza® is still readily available in U.S. pharmacies (including mail-order), and if needed, pharmacies can order additional supplies from wholesalers with expected delivery within 1-2 days. As the global situation evolves, we will continue to take the necessary steps to safeguard the reliable supply of Afrezza®.


Other Resources


Together with the JDRF & Beyond Type 1 Alliance, MannKind is sharing guidance on recommendations for people living with diabetes to reduce risk of complications caused by the coronavirus.

Check out www.coronavirusdiabetes.org to see the list of recommendations, downloadable graphics, videos and links to additional resources – many available in both English and Spanish!


US-AFR-0990

Important Safety Information for Afrezza® (insulin human) Inhalation Powder

Afrezza® can cause serious side effects, including: Sudden lung problems (bronchospasms). Do not use Afrezza® if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting Afrezza®, your healthcare provider will give you a breathing test to check how your lungs are working.

Important Safety Information

What is the most important information I should know about Afrezza®?

Afrezza® can cause serious side effects, including:
Sudden lung problems (bronchospasms). Do not use Afrezza® if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting Afrezza®, your healthcare provider will give you a breathing test to check how your lungs are working.

  • Afrezza® is a man-made insulin that is breathed-in through your lungs (inhaled) and is used to control high blood sugar in adults with diabetes mellitus.
  • Afrezza® is not for use in place of long-acting insulin. Afrezza® must be used with long-acting insulin in people who have type 1 diabetes mellitus.
  • Afrezza® is not for use to treat diabetic ketoacidosis.
  • It is not known if Afrezza® is safe and effective for use in people who smoke. Afrezza® is not for use in people who smoke or have recently stopped smoking (less than 6 months).
  • It is not known if Afrezza® is safe and effective in children under 18 years of age.

Do not use Afrezza® if you:

  • Have chronic lung problems such as asthma or COPD.
  • Are allergic to regular human insulin or any of the ingredients in Afrezza®. See the end of this Medication Guide for a complete list of ingredients in Afrezza®.

Before using Afrezza®, tell your healthcare provider about all your medical conditions, including if you:

  • Have lung problems such as asthma or COPD
  • Have or have had lung cancer
  • Are using any inhaled medications
  • Smoke or have recently stopped smoking
  • Have kidney or liver problems
  • Are pregnant, planning to become pregnant, or are breastfeeding. Afrezza® may harm your unborn or breastfeeding baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.

Before you start using Afrezza®, talk to your healthcare provider about low blood sugar and how to manage it.

  • Read the detailed Instructions for Use that comes with your Afrezza®.
  • Take Afrezza® exactly as your healthcare provider tells you to. Your healthcare provider should tell you how much Afrezza® to use and when to use it.
  • Know the strength of Afrezza® you use. Do not change the amount of Afrezza® you use unless your healthcare provider tells you to.
  • Take Afrezza® at the beginning of your meal.
  • Check your blood sugar levels. Ask your healthcare provider what your blood sugar should be and when you should check your blood sugar levels.
  • Keep Afrezza® and all medicines out of the reach of children.

  • Change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, or because of other medicines you take.

While using Afrezza® do not:

  • Drive or operate heavy machinery, until you know how Afrezza® affects you.
  • Drink alcohol or use over-the-counter medicines that contain alcohol.
  • Smoke.

Afrezza® may cause serious side effects that can lead to death, including:

See “What is the most important information I should know about Afrezza®?” at the top of this page.

  • Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include:

    • Dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, hunger.
  • Decreased lung function. Your healthcare provider should check how your lungs are working before you start using Afrezza®, 6 months after you start using it and yearly after that.
  • Lung cancer. In studies of Afrezza® in people with diabetes, lung cancer occurred in a few more people who were taking Afrezza® than in people who were taking other diabetes medications. There were too few cases to know if lung cancer was related to Afrezza®. If you have lung cancer, you and your healthcare provider should decide if you should use Afrezza®.
  • Diabetic ketoacidosis. Talk to your healthcare provider if you have an illness. Your Afrezza® dose or how often you check your blood sugar may need to be changed.
  • Severe allergic reaction (whole body reaction). Get medical help right away if you have any of these signs or symptoms of a severe allergic reaction:

    • A rash over your whole body, trouble breathing, a fast heartbeat, or sweating.
  • Low potassium in your blood (hypokalemia).
  • Heart failure. Taking certain diabetes pills called thiazolidinediones or “TZDs” with Afrezza® may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with Afrezza®. Your healthcare provider should monitor you closely while you are taking TZDs with Afrezza®. Tell your healthcare provider if you have any new or worse symptoms of heart failure including:

    • Shortness of breath, swelling of your ankles or feet, sudden weight gain.

Treatment with TZDs and Afrezza® may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.

Get emergency medical help if you have:

• Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.

The most common side effects of Afrezza® include:

  • Low blood sugar (hypoglycemia), cough, sore throat

These are not all the possible side effects of Afrezza®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088).

Active ingredient: human insulin

Inactive ingredients: fumaryl diketopiperazine, polysorbate 80

General information about the safe and effective use of Afrezza®.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Afrezza® for a condition for which it was not prescribed. Do not give Afrezza® to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about Afrezza®. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about Afrezza® that is written for health professionals.

AFREZZA®, MANNKIND, and the Afrezza® and MannKind logos are registered marks, all owned by MannKind Corporation. © MannKind Corporation 2020.
This site is intended for use by U.S. residents only